LCM
KNSA icon

Lynx1 Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Lynx1 Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,231
Closed -$206K – 20
2024
Q3 		$206K Sell
8,231
-1,269
-13% -$30.9K 0.07% 15
2024
Q2 		$177K Buy
+9,500
New +$178K 0.06% 14

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Lynx1 Capital Management's KNSA Position: Q4 2024 in Review

Lynx1 Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 8,231 shares — an estimated $206K sold.

Lynx1 Capital Management first reported a position in KNSA in Q2 2024 and held it in 2 quarters. The position peaked at $206K in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

  • Lynx1 Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Lynx1 Capital Management sold 8,231 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $206K.
  • Lynx1 Capital Management first reported a position in Kiniksa Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Lynx1 Capital Management's Kiniksa Pharmaceuticals position peaked at $206K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on Lynx1 Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.